Director, Memory Disorders and Alzheimer's Division, Professor of Neurology, Barrow Neurological Institute. Professor, Neurology, UA College of Medicine-Phoenix
Neurology
Dr. Marwan N. Sabbagh, MD
|
|
Give Review
Dr. Marwan N. Sabbagh is an expert in the field of Neurology. He went to University of Arizona College of Medicine - Tucson. University of Arizona College of Medicine - Tucson is ranked 67 in research and 42 in primary care medicine He has 11 awards "WestMarc Innovator Award", "CMS Meaningful Use Stage 1 Certification", "Fellow", "Healthcare Hero Finalist", "Life Member of the National Registry of Whos Who #172142", "Dystonia Doctor of Excellence", "Peter F Drucker Award Co-recipient", "Travel Fellowship Award Recipient", "Allistair Karmody Award Finalist", "Student Summer Fellow" and "Super Doctor". Marwan Sabbagh is also a published physician. He has 100 paper published. The most recent paper is: Sensitivity to change and prediction of global change for the Alzheimer's Questionnaire. He accepts Medicare.
Publications
- Differential spectral quantitative electroencephalography patterns between control and Parkinson's Disease cohorts.
- Neuropsychological Correlates of the Alzheimer's Questionnaire.
- Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's Disease.
- Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.
- Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program.
- Down syndrome and Alzheimer's Disease: Common pathways, common goals.
- Longitudinal EEG Changes Correlate with Cognitive Measure Deterioration in Parkinson's Disease.
- Arizona Alzheimer's Registry: Strategy and Outcomes of a Statewide Research Recruitment Registry.
- Olfactory dysfunction in incidental Lewy body Disease and Parkinson's Disease.
- Clinical Characterization of Mild Cognitive Impairment as a Prodrome to Dementia With Lewy Bodies.
- Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations.
- Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions.
- Investigational drugs in Alzheimer's Disease: current progress.
- Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinson's Disease subjects.
- Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimer's Disease.
- Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer Disease.
- Clinicopathological outcomes of prospectively followed normal elderly Brain bank volunteers.
- Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study.
- Erratum to: Successes and Failures for Drugs in Late-Stage Development for Alzheimer's Disease.
- Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's Disease.
- Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates.
- Autonomic complaints in patients with restless legs syndrome.
- A cellular model of amyloid precursor protein processing and amyloid-β peptide production.
- Successes and Failures for Drugs in Late-Stage Development for Alzheimer's Disease.
- (Hot Topic: Neurodegeneration: The First IBRO-Middle East Neuroscience Conference).
- Type 2 Diabetes Is Associated With Increased Alzheimer's Disease Neuropathology in ApoE ε4 Carriers.
- Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder.
- High-Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease: Drug Profile and Clinical Guidelines.
- Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically Normal older individuals.
- Tau is reduced in AD plasma and validation of employed ELISA methods.
- Changes in properties of serine 129 phosphorylated ?-synuclein with progression of Lewy-type histopathology in human Brains.
- Submandibular gland biopsy for the diagnosis of Parkinson Disease.
- Apolipoprotein E ?4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer Disease.
- Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's Disease dementia, mild cognitive impairment, and normal aging.
- Alzheimer Disease periventricular white matter lesions exhibit specific proteomic profile alterations.
- Neurochemical profile of Dementia pugilistica.
- Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies.
- BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem Brains.
- KIF6 719Arg allele is associated with statin effects on cholesterol levels in amnestic mild cognitive impairment and Alzheimer's Disease patients.
- Is There Inflammatory Synergy in Type II Diabetes Mellitus and Alzheimer's Disease?
- Can platelet BACE1 levels be used as a biomarker for Alzheimer's Disease? Proof-of-concept study.
- Autonomic function, as self-reported on the SCOPA-autonomic questionnaire, is normal in essential tremor but not in Parkinson's Disease.
- The use of informant-based questionnaires in differentiating mild cognitive impairment from Normal aging.
- Morphological and pathological evolution of the brain microcirculation in aging and Alzheimer's Disease.
- Validation and diagnostic accuracy of the Alzheimer's questionnaire.
- Novel therapeutics in Alzheimer's Disease.
- The nicotinic acetylcholine receptor: smoking and alzheimer's Disease revisited.
- Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimer's Disease.
- Striatal Amyloid Plaque Density Predicts Braak Neurofibrillary Stage and Clinicopathological Alzheimer's Disease: Implications for Amyloid Imaging.
- Positron Emission Tomography and Neuropathologic Estimates of Fibrillar Amyloid-? in a Patient With Down Syndrome and Alzheimer Disease.
- Brain biochemistry in autopsied patients with essential tremor.
- Development of a specific ELISA to measure BACE1 levels in human tissues.
- Frequency of Alzheimer's Disease pathology at autopsy in patients with clinical normal pressure hydrocephalus.
- Incidental Lewy body Disease: Electrophysiological findings suggesting pre-clinical Lewy body disorders.
- Parkinson's Disease, cortical dysfunction, and alpha-synuclein.
- Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's Disease.
- Investigational drugs for the treatment of AD: what can we learn from negative trials?
- Probable RBD is increased in Parkinson's Disease but not in essential tremor or restless legs syndrome.
- Neuropathological findings of PSP in the elderly without clinical PSP: Possible incidental PSP?
- Intracranial atherosclerosis as a contributing factor to Alzheimer's Disease dementia.
- Transcranial Doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer's Disease.
- Alzheimer's Disease and Non-Demented High Pathology Control Nonagenarians: Comparing and Contrasting the Biochemistry of Cognitively Successful Aging.
- PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease.
- Incidental Lewy body Disease: clinical comparison to a control cohort.
- Commentary on "Design of comprehensive Alzheimer's Disease centers to address unmet national needs".
- Patients with Alzheimer Disease have altered transmitral flow: echocardiographic analysis of the vortex formation time.
- On cholesterol levels and statins in cognitive decline and Alzheimer Disease: progress and setbacks.
- Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect.
- Correlation of clinical features with argyrophilic grains at autopsy.
- Parkinson Disease with dementia: comparing patients with and without Alzheimer pathology.
- Drug development for Alzheimer's Disease: where are we now and where are we headed?
- Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." A national registry to identify a cohort for Alzheimer's Disease preve...
- A roadmap for the prevention of Dementia II: Leon Thal Symposium 2008.
- Response to Parkinnen et al. and Jellinger.
- Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body Disorders.
- Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's Disease.
- Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials.
- Detecting Alzheimer Disease before it happens: The key to prevention?
- Challenges to the recognition and assessment of Alzheimer's Disease in American Indians of the southwestern United States.
- Commentary on "the Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics".
- Interactions of stroke, nonsteroidal anti-inflammatory drugs, and APOE status in Dementia risk.
- Disease-modifying approaches to Alzheimer's Disease: challenges and opportunities-Lessons from donepezil therapy.
- Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins.
- Defining mild cognitive impairment in Parkinson's Disease.
- Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer Disease, and normal aging.
- Corticomuscular coherence is increased in the small postural tremor of Parkinson's Disease.
- Do cholinergic therapies have Disease-modifying effects in Alzheimer's Disease?
- Atorvastatin for the treatment of mild to moderate Alzheimer Disease: preliminary results.
- Case series of clinically probable Dementia with Lewy bodies in two Native Americans.
- Sensitivity to expectancy violations in healthy aging and mild cognitive impairment.
- Abnormal corticomuscular coherence is associated with the small amplitude cortical myoclonus in Parkinson's Disease.
- Neuropathological and biochemical assessments of an Alzheimer's Disease patient treated with the γ-secretase inhibitor semagacestat.
- Profiles of Extracellular miRNA in Cerebrospinal Fluid and Serum from Patients with Alzheimer's and Parkinson's Diseases Correlate with Disease Status and Features of ...
- Bapineuzumab alters a? composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy.
- KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimer's Disease Patients.
- Subjects harboring presenilin familial Alzheimer's Disease mutations exhibit diverse white matter biochemistry alterations.
- The influence of Apolipoprotein E genotype on regional pathology in Alzheimer's Disease.
- Sensitivity to change and prediction of global change for the Alzheimer's Questionnaire.
- SMG1 Identified as a Regulator of Parkinson's Disease-Associated alpha-Synuclein through siRNA Screening.
Schools
University of Arizona
Good Samaritan Regional Med Center
Baylor College Of Med
University Calif
Procedures Preformed
- EEG (Electroencephalogram)
- EMG (Electromyography)
Conditions Treated
- Alzheimer's Disease
- Anterior Horn Disease
- Ataxia
- Autonomic Disorders
- View All
Doctors Specialties
- Neurology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Whole Health Banner Health Network HMO
- American Enterprise Group
- American Republic
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Cofinity PPO
- First Health (Coventry Health Care) PPO
- Golden Rule
- Health Net HMO
- Health Net PPO
- Medicare Advantage PFFS
- HealthPartners
- Humana
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Heritage Signature
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
- Wells Fargo Insurance
Awards
- WestMarc Innovator Award
- CMS Meaningful Use Stage 1 Certification
- Fellow
- Healthcare Hero Finalist
- Life Member of the National Registry of Who’s Who #172142
- Dystonia Doctor of Excellence
- Peter F Drucker Award Co-recipient
- Travel Fellowship Award Recipient
- Allistair Karmody Award Finalist
- Student Summer Fellow
- Super Doctor
Education
-
University of California San Diego -
Baylor College of Medicine -
Banner Good Samaritan Medical Center -
University of Arizona College of Medicine - Tucson
Drug Facts
| NPI NUMBER | 1497748289 | |
| NPPES Provider LastName | SABBAGH | |
| NPPES Provider FirstName | MARWAN | |
| NPPES Provider ZIPCode | 85351 | |
| NPPES Provider State | AZ | |
| Specialty Description | Neurology | |
| Total Claim Count | 3436.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 12.0 | |
| Percent Opioid Claims | 0.35 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1497748289 |
| Last Name Of The Provider | SABBAGH |
| First Name Of The Provider | MARWAN |
| View All |
Similar Doctors
|
Dr. Andre Hagevik, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Atul Syal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mohammad A. Khan, MD |
|
|
Dr. Holly A. Shill, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vito Deldel, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Todd C. Herman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ahmad Nizam, MD
This Doctor is OpenDoctor Recommended.
|